Supplement Table 1. Baseline characteristics of the PURE study participants
*Total group n = 1,697
Age (years) 48.3 (41.9, 56.4)
Sex n (%)
Men 643 (37.9)
Women 1,054 (62.1)
Rural/urban status n (%)
Rural 870 (51.3)
Urban 827 (48.7)
Tobacco use n (%)
Never 897 (52.9)
Current 737 (43.4)
Former 63 (3.7)
Alcohol use n (%)
Never 937 (55.2)
Current 686 (40.4)
Former 74 (4.4)
Waist circumference (cm) 77.0 (70.2, 87.6) PAI-1act (IU/mL) 4.25 (1.27, 7.91) PAI-1 4G/5G
polymorphism n (%)
5G/5G 1,232 (72.6)
4G/5G 422 (24.9)
4G/4G 43 (2.5)
HIV positive n (%) 276 (16.3)
HDL-C (mmol/L) 1.42 (1.06, 1.88) LDL-C (mmol/L) 2.78 (2.07, 3.63) Triglycerides (mmol/L) 1.08 (0.82, 1.55)
CRP (mg/L) 3.25 (0.95, 9.29)
GGT (U/L) 46.0 (29.5, 87.0)
Female contraceptive use n (%)
370 (35.1)
Supplement Table 2. PAI-1 4G/5G polymorphism vs central pulse pressure (cPP)
Total PAI-1 polymorphism cPP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=17) 46.93 (39.76, 54.09) 0.2645 0.2845 4G/5G (n=189) 40.98 (38.82, 43.14) 0.9847
5G/5G (n=547) 41.19 (39.85, 42.52) Ref.
Model 2 4G/4G 44.36 (38.89, 50.60) 0.4503 0.2492
4G/5G 40.56 (38.99, 42.20) 0.9459
5G/5G 40.87 (39.93, 41.82) Ref.
Model 3 4G/4G 43.84 (38.48, 49.95) 0.5507 0.2418
4G/5G 40.60 (39.04, 42.22) 0.9564
5G/5G 40.87 (39.94, 41.81) Ref.
Men PAI-1 polymorphism cPP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=2) 46.65 (27.14, 66.17) 0.8758 0.3595 4G/5G (n=66) 39.09 (35.72, 42.46) 0.3880
5G/5G (n=164) 41.76 (39.61, 43.92) Ref.
Model 2 4G/4G 41.22 (27.75, 61.23) 0.9947 0.4242
4G/5G 39.14 (36.52, 41.95) 0.7259
5G/5G 40.41 (38.69, 42.21) Ref.
Model 3 4G/4G 41.26 (27.87, 61.07) 0.9942 0.4178
4G/5G 39.12 (36.52, 41.90) 0.7111
5G/5G 40.42 (38.72, 42.20) Ref.
Women PAI-1 polymorphism cPP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=15) 47.22 (39.43, 55.01) 0.2924 0.2829 4G/5G (n=123) 42.24 (39.51, 44.97) 0.7784
5G/5G (n=383) 41.17 (39.62, 42.71) Ref.
Model 2 4G/4G 44.98 (39.12, 51.71) 0.4206 0.4042
4G/5G 41.32 (39.35, 43.39) 0.9751
5G/5G 41.07 (39.95, 42.21) Ref.
Model 3 4G/4G 44.40 (38.67, 50.98) 0.5223 0.3959
4G/5G 41.37 (39.42, 43.42) 0.9644
5G/5G 41.07 (39.97, 42.20) Ref.
Notes: model 1: age, rural/urban status and sex adjusted; model 2 is model 1 supplementary adjusted for high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, C-reactive protein, γ- glutamyl transferase, HIV status and anti-hypertensive medication use; model 3 is model 2 supplementary adjusted for waist circumference. All analyses conducted in women were supplementary adjusted for contraceptive use. pdifference is the p-value comparing outcome LS mean by PAI-1 polymorphism; pomnibus is the Type-III test for the overall effect of PAI-1 polymorphism.
Supplement Table 3. PAI-1 4G/5G polymorphism vs waist circumference (WC)
Total PAI-1 polymorphism WC LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=43) 81.53 (78.62, 84.43) 0.8629 0.1398 4G/5G (n=422) 79.74 (78.81, 80.67) 0.1494
5G/5G (n=1232) 80.75 (80.21, 81.29) Ref.
Model 2 4G/4G 81.22 (78.50, 83.94) 0.9831 0.1928
4G/5G 80.07 (79.19, 80.94) 0.1752
5G/5G 80.97 (80.47, 81.48) Ref.
Men PAI-1 polymorphism WC LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=10) 78.11 (72.85, 83.38) 0.9935 0.1657 4G/5G (n=167) 76.53 (75.37, 77.69) 0.1438
5G/5G (n=466) 77.82 (77.14, 78.50) Ref.
Model 2 4G/4G 78.90 (74.10, 83.70) 0.8908 0.2790
4G/5G 76.82 (75.76, 77.89) 0.2917
5G/5G 77.77 (77.15, 78.39) Ref.
Women PAI-1 polymorphism WC LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=33) 84.67 (81.15, 88.19) 0.8844 0.3769 4G/5G (n=255) 82.86 (81.57, 84.15) 0.4164
5G/5G (n=766) 83.81 (83.10, 84.52) Ref.
Model 2 4G/4G 83.73 (80.45, 87.01) 0.9911 0.2977
4G/5G 82.85 (81.65, 84.06) 0.2647
5G/5G 83.95 (83.28, 84.61) Ref.
Supplement Table 4. PAI-1 4G/5G polymorphism vs brachial systolic blood pressure (bSBP)
Total PAI-1 polymorphism bSBP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=43) 140.7 (133.9, 147.8) 0.0735 0.1152 4G/5G (n=422) 133.3 (131.0, 135.6) 0.3758
5G/5G (n=1232) 134.4 (132.7, 136.1) Ref.
Model 2 4G/4G 136.9 (130.6, 143.5) 0.0741 0.1829
4G/5G 130.7 (128.8, 132.7) 0.7744
5G/5G 131.1 (129.9, 132.2) Ref.
Model 3 4G/4G 136.6 (130.4, 143.1) 0.0855 0.2114
4G/5G 130.8 (128.9, 132.7) 0.8200
5G/5G 131.1 (129.9, 132.2) Ref.
Men PAI-1 polymorphism bSBP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=10) 136.3 (123.0, 150.9) 0.9832 0.8148 4G/5G (n=167) 134.8 (131.2, 138.5) 0.5248
5G/5G (n=466) 136.1 (133.5, 138.7) Ref.
Model 2 4G/4G 133.3 (121.0, 146.8) 0.9556 0.8635
4G/5G 132.6 (129.5, 135.8) 0.5882
5G/5G 133.6 (131.8, 135.5) Ref.
Model 3 4G/4G 133.3 (121.1, 146.8) 0.9690 0.9025
4G/5G 132.8 (129.7, 135.9) 0.6632
5G/5G 133.6 (131.7, 135.5) Ref.
Women PAI-1 polymorphism bSBP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=33) 142.0 (134.2, 150.3) 0.0217 0.0509 4G/5G (n=255) 132.0 (129.1, 134.9) 0.5587
5G/5G (n=766) 132.9 (130.8, 135.0) Ref.
Model 2 4G/4G 137.4 (130.2, 145.0) 0.0358 0.1098
4G/5G 129.7 (127.2, 132.2) 0.9080
5G/5G 129.5 (128.1, 131.0) Ref.
Model 3 4G/4G 137.1 (130.0, 144.6) 0.0378 0.1151
4G/5G 129.7 (127.1, 132.3) 0.8946
5G/5G 129.5 (127.9, 131.1) Ref.
Notes: model 1: age, rural/urban status and sex adjusted; model 2 is model 1 supplementary adjusted for high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, C-reactive protein, γ- glutamyl transferase, HIV status and anti-hypertensive medication use; model 3 is model 2 supplementary adjusted for waist circumference. All analyses conducted in women were supplementary adjusted for contraceptive use. pdifference is the p-value comparing outcome LS mean by PAI-1 polymorphism; pomnibus is the Type-III test for the overall effect of PAI-1 polymorphism.
Supplement Table 5. PAI-1 4G/5G polymorphism vs brachial diastolic blood pressure (bDBP)
Total PAI-1 polymorphism bDBP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=43) 90.7 (86.3, 95.3) 0.1453 0.3433
4G/5G (n=422) 87.3 (85.8, 88.8) 0.1589 5G/5G (n=1232) 87.5 (86.4, 88.6) Ref.
Model 2 4G/4G 88.5 (84.4, 92.8) 0.4772 0.4884
4G/5G 86.3 (85.1, 87.7) 0.9147
5G/5G 86.0 (85.3, 86.8) Ref.
Model 3 4G/4G 88.3 (84.3, 92.5) 0.2817 0.5204
4G/5G 86.4 (85.1, 87.7) 0.6301
5G/5G 86.0 (85.3, 86.8) Ref.
Men PAI-1 polymorphism bDBP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=10) 84.0 (75.5, 93.5) 0.5739 0.8278
4G/5G (n=167) 87.0 (84.6, 89.4) 0.8376 5G/5G (n=466) 86.7 (85.0, 88.4) Ref.
Model 2 4G/4G 82.8 (74.8, 91.6) 0.5692 0.7999
4G/5G 85.6 (83.5, 87.8) 0.7604
5G/5G 85.3 (84.0, 86.5) Ref.
Model 3 4G/4G 82.8 (74.9, 91.6) 0.5779 0.7704
4G/5G 85.7 (83.7, 87.9) 0.6774
5G/5G 85.2 (84.0, 86.5) Ref.
Women PAI-1 polymorphism bDBP LS mean (95% CI) pdifference pomnibus
Model 1 4G/4G (n=33) 92.7 (87.7, 97.9) 0.0584 0.1378
4G/5G (n=255) 87.4 (85.5, 89.3) 0.6743 5G/5G (n=766) 87.8 (86.5, 89.1) Ref.
Model 2 4G/4G 90.5 (85.8, 95.5) 0.1030 0.2640
4G/5G 86.8 (85.1, 88.4) 0.8175
5G/5G 86.5 (85.6, 87.5) Ref.
Model 3 4G/4G 90.4 (85.8, 95.2) 0.1095 0.2764
4G/5G 86.8 (85.1, 88.5) 0.7993
5G/5G 86.5 (85.5, 87.6) Ref.
Notes: model 1: age, rural/urban status and sex adjusted; model 2 is model 1 supplementary adjusted for
